193269-78-2

Usage

Chemical Properties

Clear Colourless to Pale Yellow Oil

InChI:InChI=1/C8H16N2O2/c1-8(2,3)12-7(11)10-4-6(9)5-10/h6H,4-5,9H2,1-3H3

Upstream product

• 429672-02-6 tert-butyl 3-azidoazetidine-1-carboxylate 
• 141699-55-0 tert-butyl 3-hydroxyazetidine-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 254454-54-1 tert-butyl-3-iodoazetidine-1-carboxylate 

Downstream Products

• 930294-79-4 N-(tert-butyloxycarbonyl)-3-(2-nitrobenzenesulfonyl)aminoazetidine 
• 1033844-25-5 tert-butyl 3-(2-(3-fluorophenyl)nicotinamido)azetidine-1-carboxylate 
• 1228652-17-2 3-[2-(3-trifluoro-methyl-benzoylamino)-acetylamino]-azetidine-1-carboxylic acid tert-butyl ester 
• 1352933-45-9 tert-butyl 3-(2-(((benzyloxy)carbonyl)amino)acetamido)azetidine-1-carboxylate 
• 1352934-66-7 tert-butyl 3-(2-(((benzyloxy)carbonyl)(methyl)amino)acetamido)azetidine-1-carboxylate 
• 1352934-25-8 tert-butyl 3-(2-(((benzyloxy)carbonyl)(6-(trifluoromethyl)quinolin-4-yl)amino)acetamido)azetidine-1-carboxylate 
• 1239361-83-1 (S)-1-{2-[1-(4-fluorophenyl)indolylethylamino]-6-(aminopyrazine-2-ylamino)-4-yl}ethanone 
• 939760-33-5 tert-butyl 3-(benzylamino)azetidine-1-carboxylate 
• 1362804-75-8 tert-butyl 3-(benzyl(methyl)amino)azetidine-1-carboxylate 
• 1198160-21-2 tert-butyl 3-(1-oxo-3-{[4-(trifluoromethoxy)benzyl]carbamoyl}-1,3-dihydro-2H-isoindol-2-yl)azetidine-1-carboxylate 
• 1416984-80-9 C₁₅H₁₈Cl₂N₂O₃ 
• 1342837-20-0 tert-butyl 3-((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methylamino)azetidine-1-carboxylate 
• 1342837-24-4 tert-butyl 3-(((6-(7-(4-(3-cyclopropylureido)-2-fluorophenoxy)thieno[3,2-b]pyridin-2-yl)pyridin-3-yl)methyl)(2-ethoxy-2-oxoethyl)amino)azetidine-1-carboxylate 
• 1429307-76-5 tert-butyl 3-(3-(4-(2-(5-(1,3-dioxolan-2-yl)pyridin-2-yl)thieno[3,2-b]pyridin-7-yloxy)-3-fluorophenyl)ureido)azetidine-1-carboxylate 

Relevant academic research and scientific papers

FUSED HETEROCYCLIC COMPOUND

The present invention relates to a fused heterocyclic compound having the Formula 1, which is useful as a platelet aggregation inhibitor, a method for preparing the same, and a pharmaceutical composition for inhibiting platelet aggregation comprising the same.

CARBAPENEM ANTIBACTERIALS WITH GRAM-NEGATIVE ACTIVITY

The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions. The invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment.

N-HETEROCYCLYL-SUBSTITUTED AMINO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS

Aminothiazole compounds with N-containing cycloalkyl at the 2-amino position which are represented by the Formula (I), or a pharmaceutically acceptable prodrug of said compound, or pharmaceutically acceptable salt of said compound, modulate and/or inhibit the cell proliferation and activity of protein kinases.

Pharmaceutically active pyrrolidine derivatives

The present invention is related to pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of premature labor, premature birth and dysmenorrhea. In particular, the present invention is related to pyrrolidine derivatives displaying a substantial modulatory, notably an antagonist activity of the oxytocin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin, including premature labor, premature birth and dysmenorrhea. The present invention is furthermore related to novel pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of CR6R7, NOR6, NNR6R7; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO22—, —SO2NH—, —CH2—,B is either a group —(C═O)—NR8R9 or represents a heterocyclic residue having the formula (a) wherein Q is NR10, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

Pharmaceutically active pyrrolidine derivatives as bax inhibitors

The present invention is related to new substituted pyrrolidine derivatives of formula (I). Said compounds are preferably for use as pharmaceutically active compounds. Specifically, pyrrolidine derivatives of formula (I) are useful in the treatment and/or prevention of neurodegenerative disorders, diseases associated with polygultamine tracts, epilepsy, ischemia, infertility, cardiovascular disorders renal hypoxia, hepatitis and AIDS. Said pyrrolidine derivatives display a modulatory and most notably a down-regulating-up to an inhibitory-activity with respect to the cellular death agonist Bax and/or the activation pathways leading to Bax and allows therefore to block the release of cytochrome (c). The present invention is furthermore related to novel pharmaceutically activity substituted pyrrolidine derivatives as well as to methods of their preparation, wherein X is selected from the group consisting of O, S, CRR, NOR, NNRR; A is selected from the group consisting of —(C═O)—, —(C═O)—O—, —C(═NH)—, —(C═O)—NH—, —(C═S)—NH, —SO2-, —SO2NH—; —CH2-; B is either a group —(C═O)—NRR or represents a heterocyclic residue having the formula (II) wherein Q is NR, O or S; n is an integer selected of 0, 1 or 2; Y, Z and E form together with the 2 carbons to which they are attached a 5-6 membered aryl or heteroaryl ring.

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

PROCOLLAGEN C-PROTEINASE INHIBITORS

and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.